GSK Chief Optimistic About BD Despite Volatile Environment

30 Apr 2025

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Dame Emma Walmsley — Emma Walmsley • Source: GSK

The uncertainty created by potential tariffs and US healthcare strategies has seen some senior pharma figures express concern about the impact on M&A but GSK CEO Emma Walmsley is confident that dealmaking will continue to thrive.

Key Takeaways

The GSK CEO is ‘constantly looking’ at BD opportunities, not least in China.

Thomas Schinecker, her counterpart at Roche, cautioned last week that trade barriers and greater demand for investment in US manufacturing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

13 Jun 2025

• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

BioNTech To Buy mRNA Rivals CureVac

12 Jun 2025

• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.